Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70091 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Akinori Nakashima und 5 weiteren Autor:innen. Beteiligte Einrichtung: Japan Pharmaceutical Manufacturers Association Clinical Evaluation Expert Committee, Drug Evaluation Committee, Tokyo, Japan. Hauptthemen laut MEDLINE: Drug Development, Models, Biological. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In Japan, the percentage of approved drugs with pediatric indications increased to 30% in 2010‐2015, but no further increase was observed through 2020. The Ministry of Health, Labor, and Welfare in Japan presented draft future directions to promote pediatric drug development, where the modeling and simulation (M&S) approach was introduced as a tool to support efficacy and safety, utilizing existing data when building a flexible data package for pediatric drug approval. M&S is considered a powerful scientific tool in pediatric drug development using the pediatric extrapolation approach. We examined approval application data packages for pediatric drugs approved in Japan from January 2019 to March 2023, where 95 drug products were identified as pediatric drugs for this survey. Drugs with complete, partial, or no extrapolation accounted for 43.2%, 30.5%, and 26.3% of the total drugs, respectively. M&S was widely used as the major rationale in dose selection for pediatric clinical trials and/or the recommended dosing regimen in drug approval applications for the pediatric population (60.0%). Further use of existing data with extrapolation strategies may lead to the development of flexible and efficient data packages for pediatric drug approval. Since safety profiles may be different between pediatric and adult populations due to age‐related factors, pediatric developmental safety should be incorporated into M&S in future assessments. The pharmaceutical industry, regulatory authorities, and academia need to discuss development strategies from an early stage and share lessons learned, thereby facilitating further discussions on efficient pediatric drug development and delivering drugs for children without delay in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Japan Pharmaceutical Manufacturers Association Clinical Evaluation Expert Committee, Drug Evaluation Committee, Tokyo, Japan.
- Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
- Clinical Development, R&D Japan, Bristol Myers Squibb K.K., Tokyo, Japan.
- Modeling & Simulation, Astellas Pharma, Inc., Tokyo, Japan.
- Quantitative Sciences and Evidence Generation, Astellas Pharma, Inc., Tokyo, Japan.
- Asia Pacific Project Leader group, R&D, Janssen Pharmaceutical K.K., Tokyo, Japan.
ORCID-Profile: Akihide Tsujimoto
Zitieren
APA
Nakashima, A., Tsujimoto, A., Saito, M., Takeda, J., Natori, M., & Shoji, S. (2025). Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70091
Vancouver
Nakashima A, Tsujimoto A, Saito M, Takeda J, Natori M, Shoji S. Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70091
BibTeX
@article{Nakashima2025,
author = {Nakashima, Akinori and Tsujimoto, Akihide and Saito, Masako and Takeda, Jun and Natori, Makiko and Shoji, Satoshi},
title = {Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70091}
}
EUVIMED